Phenotypes associated with heterozygous alterations were described in B cell lymphoma and Rubinstein-Taybi syndrome 1 (41, 42), suggesting dosage-dependent EP300/CBP function. The gene discussed is CREBBP; the disease is Rubinstein-Taybi syndrome due to CREBBP mutations.